Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Strati

Showing results (101-110 of 139) with videos related to

Pageof 14
Sort By:
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Blood Advances|June 27, 2020
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C Pinnix, Jillian R Gunther, Bouthaina S Dabaja, et al.
Advances in Radiation Oncology|November 18, 2024
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?Penny Fang, Sonal S Noticewala, Susan Y Wu, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Haematologica|November 30, 2023
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapyAndrew P Jallouk, Naishu Kui, Ryan Sun, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Blood Advances|March 31, 2022
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximabMario L Marques-Piubelli, Edwin R Parra, Lei Feng, et al.
Pageof 14

Showing results (101-110 of 139) with videos related to

Sort By:
Pageof 14
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphomaEhsan Irajizad, Johannes F Fahrmann, Hiroyuki Katayama, et al.
Blood Advances|June 27, 2020
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomaChelsea C Pinnix, Jillian R Gunther, Bouthaina S Dabaja, et al.
Advances in Radiation Oncology|November 18, 2024
Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?Penny Fang, Sonal S Noticewala, Susan Y Wu, et al.
Advances in Radiation Oncology|November 11, 2024
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the LungSusan Y Wu, Penny Q Fang, Ahmed Fetooh, et al.
Blood Advances|February 5, 2025
Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomasDai Chihara, Raphael E Steiner, Ranjit Nair, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Haematologica|November 30, 2023
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapyAndrew P Jallouk, Naishu Kui, Ryan Sun, et al.
Frontiers in Oncology|September 26, 2024
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organsGohar S Manzar, Elaine E Cha, Kelsey L Corrigan, et al.
Leukemia & Lymphoma|January 24, 2020
Pretreatment SUV<sub>max</sub> may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FLPaolo Strati, Mohamed Amin Ahmed, Loretta J Nastoupil, et al.
Blood Advances|March 31, 2022
SIRPα+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximabMario L Marques-Piubelli, Edwin R Parra, Lei Feng, et al.
Pageof 14